Evidence map›Paper›PMID 40852433›Full record

ArticleFrontiers in veterinary science2025

Preparation and pharmacokinetic study of mebendazole complex with HP-beta-cyclodextrin.

Charles Ding, Yili Ding, Zhe Xu, Peini Wang, Shufeng Xu

Abstract read
In one paragraph

Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles DingCollege of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, China.
Yili DingCollege of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, China.
Zhe XuCollege of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, China.
Peini WangCollege of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, China.
Shufeng XuLife Science Department, Foshan University, Foshan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mebendazole, approved by the Food and Drug Administration (FDA) in 1974 to expel intestinal parasite infections, was found to exhibit multiple anti-cancer activities. However, due to its poor water solubility (0.33 ± 0.02 μg/mL), its clinical applications were greatly limited. Scientists at Wenzhou-Kean University have developed a formulation that could increase its water solubility as much as 18,333 times to reach 6.05 mg/mL as the best result to date. Through the complexation with HP-beta-cyclodextrin, 80% of mebendazole in the complex was released

Indexed as

complex preparationHP-beta-cyclodextrininclusion complexin vitro and in vivo pharmacokinetic studymebendazole

Identifiers

PMID40852433
PMCPMC12367471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.